Total Funding
20
27
Total FundingPost-IPO Debt raised
Growth Score
-1 pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
242667
Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative disorders.
Olivier Danos: Senior Vice President Molecular Medicine- Ralph Laufer: Chief Scientific Officer
About the Company
Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative disorders .
Their mission is to radically improve the health of patients suffering from incurable life threatening conditions. They do this by developing AAV vectors that have demonstrated their effectiveness in safely delivering genetic
material to the central nervous system.
